All In Biotech

Free tool

FAERS Monitor: Attruby

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216540 or its brand name (Attruby, Acoramidis Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

370

Serious

87

24% of reports

Hospitalization

49

Death reported

12

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea69
  • fatigue29
  • dizziness23
  • blood creatinine increased21
  • abdominal discomfort18
  • nausea18
  • dyspnoea16
  • weight decreased16
  • asthenia15
  • product dose omission issue15
  • abdominal pain upper13
  • rash11
  • death9
  • dysphagia9
  • gastrointestinal disorder9

Reports by year received

View as table
YearReports
2025189
2026181

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,789 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood creatinine increasedSignal2118.312.1327
abdominal discomfortSignal186.13.972
diarrhoeaSignal696.14.9297
gastrointestinal disorderSignal95.73.031
dysphagiaSignal95.42.828
abdominal pain upperSignal133.62.122
weight decreasedSignal163.32.023
product dose omission issueSignal152.91.817
dizzinessSignal232.61.822
astheniaSignal152.31.410
fatigueSignal292.11.517
dyspnoea161.61.03
rash111.40.81
nausea181.30.81
death90.60.32

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.